Article
TP53 mutation does not confer a poor outcome in adult patients with acute lymphoblastic leukemia who are treated with frontline hyper-CVAD-based regimens.
Cancer - 1 Oct 2017
Kanagal-Shamanna Rashmi, Jain Preetesh, Takahashi Koichi, Short Nicholas J, Tang Guilin, Issa Ghayas C, Ravandi Farhad, Garcia-Manero Guillermo, Yin Cameron C, Luthra Rajyalakshmi, Patel Keyur P, Khoury Joseph D, Montalban-Bravo Guillermo, Sasaki Koji, Kadia Tapan M, Borthakur Gautam, Konopleva Marina, Jain Nitin, Garris Rebecca, Pierce Sherry, Wierda William, Estrov Zeev, Cortes Jorge, O'Brien Susan, Kantarjian Hagop M, Jabbour Elias
Abstract excerpt
BACKGROUND: Tumor protein 53 (TP53) mutations are uncommon in adult patients with acute lymphoblastic leukemia (ALL) and predict a poor outcome. METHODS: TP53 mutation analysis was performed in 164 newly diagnosed adult patients with ALL using a combination of targeted amplicon-based next-generation sequencing and Sanger sequencing. RESULTS: TP53 mutations were detected in 25 patients (15%), with a median allelic...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.